Cite
HARVARD Citation
Adès, L. et al. (2022). A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher‐Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations. British journal of haematology. pp. 535-544. [Online].